BioCentury

4:38 PM GMT, Sep 21, 2018
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial

Read the full 274 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.